ライフサイエンスコーパス: chronic obstructive pulmonary disease

1 ent smoking, 0.51 for diabetes, and 0.69 for chronic obstructive pulmonary disease).

2 d in human PH (idiopathic or associated with chronic obstructive pulmonary disease).

3 body-mass index, chronic kidney disease, and chronic obstructive pulmonary disease).

4 d possible effect modification by asthma and chronic obstructive pulmonary disease.

5 and diagnostic and therapeutic approaches in chronic obstructive pulmonary disease.

6 t not in patients with acute exacerbation of chronic obstructive pulmonary disease.

7 e not been demonstrated yet in patients with chronic obstructive pulmonary disease.

8 e smoking, which is the main risk factor for chronic obstructive pulmonary disease.

9 sponse to exercise training in patients with chronic obstructive pulmonary disease.

10 disease, including cystic fibrosis (CF) and chronic obstructive pulmonary disease.

11 This might indicate an early stage of chronic obstructive pulmonary disease.

12 III or IV), and medical history of asthma or chronic obstructive pulmonary disease.

13 l inhalation therapy in patients with severe chronic obstructive pulmonary disease.

14 th underlying inflammatory diseases, such as chronic obstructive pulmonary disease.

15 s represents an early developmental phase of chronic obstructive pulmonary disease.

16 ieved to be a cofactor in the development of chronic obstructive pulmonary disease.

17 ute exacerbations in patients suffering from chronic obstructive pulmonary disease.

18 ts, specifically exacerbations of asthma and chronic obstructive pulmonary disease.

19 tes and mortality from cirrhosis, cancer, or chronic obstructive pulmonary disease.

20 y used as an inhaled treatment of asthma and chronic obstructive pulmonary disease.

21 smoke and infection are the major drivers of chronic obstructive pulmonary disease.

22 respiratory tract infections in adults with chronic obstructive pulmonary disease.

23 dividuals afflicted with cystic fibrosis and chronic obstructive pulmonary disease.

24 ongitudinally over 10 years from adults with chronic obstructive pulmonary disease.

25 ases traditionally occurring in men, such as chronic obstructive pulmonary disease.

26 a2-adrenergic receptor agonist used to treat chronic obstructive pulmonary disease.

27 h evidence of other airway diseases, such as chronic obstructive pulmonary disease.

28 nd exacerbations of both cystic fibrosis and chronic obstructive pulmonary disease.

29 a feature of several lung pathologies, e.g. chronic obstructive pulmonary disease.

30 he main goals of treatment for patients with chronic obstructive pulmonary disease.

31 ed familial aggregation, and associated with chronic obstructive pulmonary disease.

32 Major comorbidities included diabetes (21%), chronic obstructive pulmonary disease (12%), and immunos

33 .1%), coronary artery disease (15.6%-22.3%), chronic obstructive pulmonary disease (14.4%-20.1%), ane

34 ficiency (27.4%), diabetes mellitus (29.5%), chronic obstructive pulmonary disease (16.0%), and a mea

35 in (1) predicting the inception of asthma or chronic obstructive pulmonary disease, (2) inflammatory

36 s: dementia with frailty (29%), frailty with chronic obstructive pulmonary disease (25%), and frailty

37 ic cardiomyopathy (86% versus 52%; P=0.002), chronic obstructive pulmonary disease (41% versus 13%; P

38 s cardiac surgery (18% versus 12%, P<0.001), chronic obstructive pulmonary disease (5% versus 3%, P=0

39 hypertension (53.5%), diabetes (22.3%), and chronic obstructive pulmonary disease (9.4%).

40 e pathogenesis of prevalent diseases such as chronic obstructive pulmonary disease, acquired rhinosin

41 Airflow limitation compatible with chronic obstructive pulmonary disease affects almost one

42 In this study, we use a model of chronic obstructive pulmonary disease airway disease uti

43 absence of heart failure, moderate-to-severe chronic obstructive pulmonary disease, airway patency pr

44 r mechanical ventilation; moderate to severe chronic obstructive pulmonary disease; airway patency pr

45 es such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease, although the fact

46 In contrast, the higher prevalence of chronic obstructive pulmonary disease among Puerto Rican

47 idney disease (HR 1.59, 95 % CI: 1.33-1.90), chronic obstructive pulmonary disease and bronchiectasis

48 hospital admissions in patients with severe chronic obstructive pulmonary disease and chronic bronch

49 Patients with chronic lung disease, such as chronic obstructive pulmonary disease and cystic fibrosi

50 Twenty-two ex-smokers with combined chronic obstructive pulmonary disease and heart failure

51 a common finding in patients with coexistent chronic obstructive pulmonary disease and heart failure.

52 curable end-stage pulmonary diseases such as chronic obstructive pulmonary disease and idiopathic pul

53 uantified in the quadriceps of patients with chronic obstructive pulmonary disease and intensive care

54 hubs in diseases as varied phenotypically as chronic obstructive pulmonary disease and IPF and sugges

55 are the major site of airflow obstruction in chronic obstructive pulmonary disease and may precede em

56 isorders, drug use disorders, and history of chronic obstructive pulmonary disease and occupational l

57 re found primarily in central Appalachia for chronic obstructive pulmonary disease and pneumoconiosis

58 ssociated with the susceptibility to develop chronic obstructive pulmonary disease and pulmonary func

59 estive heart failure, stroke, pneumonia, and chronic obstructive pulmonary disease) and a surgical di

60 , including ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and cancers (live

61 ociated with failure to rescue were ascites, chronic obstructive pulmonary disease, and diabetes.

62 a nitrogen, sodium, cerebrovascular disease, chronic obstructive pulmonary disease, and hemoglobin, w

63 include acute respiratory distress syndrome, chronic obstructive pulmonary disease, and interstitial

64 age, body mass index, polyvascular disease, chronic obstructive pulmonary disease, and malignancy.

65 ients with idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease, and mice with ble

66 ng 127,836 cases of asthma, 298,751 cases of chronic obstructive pulmonary disease, and more than 1.1

67 s (per 10-mug/m3 increase) with respiratory, chronic obstructive pulmonary disease, and pneumonia mor

68 inflammatory lung diseases including asthma, chronic obstructive pulmonary disease, and pulmonary fib

69 s play a role in the pathogenesis of asthma, chronic obstructive pulmonary disease, and pulmonary inf

70 Older participants, those with chronic obstructive pulmonary disease, and those with mo

71 ing proportion (25% to 45%) of patients with chronic obstructive pulmonary disease are never-smokers,

72 res, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease are usually studie

73 ormal alveolar macrophages (AM) are found in chronic obstructive pulmonary disease, asthma, cystic fi

74 rious comorbidities including renal disease, chronic obstructive pulmonary disease, atrial fibrillati

75 miR-542-3p/5p were elevated in patients with chronic obstructive pulmonary disease but more markedly

76 anically ventilated patients with asthma and chronic obstructive pulmonary disease, but are not recom

77 lmonary diseases, particularly in asthma and chronic obstructive pulmonary disease, but their potenti

78 high cholesterol, stroke, arthritis, asthma, chronic obstructive pulmonary disease, cancer, weak/fail

79 he pitavastatin group (atrial septal defect, chronic obstructive pulmonary disease, chest pain, diver

80 ed 40 years or older with severe/very severe chronic obstructive pulmonary disease, chronic bronchiti

81 fraction, New York Heart Association class, chronic obstructive pulmonary disease, chronic kidney di

82 etes, hypertension, cerebrovascular disease, chronic obstructive pulmonary disease, chronic renal fai

83 lence in adults with asthma were as follows: chronic obstructive pulmonary disease (COPD) (13.4% vs 3

84 Chronic obstructive pulmonary disease (COPD) affects ove

85 ted changes in gene expression that occur in chronic obstructive pulmonary disease (COPD) after corti

86 haled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) and a histo

87 cancer (NSCLC) patients, human patients with chronic obstructive pulmonary disease (COPD) and amyotro

88 ctivity/expression in lungs of patients with chronic obstructive pulmonary disease (COPD) and asthma

89 sis of patients with characteristics of both chronic obstructive pulmonary disease (COPD) and asthma,

90 f severe obstructive lung diseases including chronic obstructive pulmonary disease (COPD) and cystic

91 Patients with chronic obstructive pulmonary disease (COPD) and in part

92 To determine how chronic obstructive pulmonary disease (COPD) and mechani

93 as a respiratory stimulant for patients with chronic obstructive pulmonary disease (COPD) and metabol

94 has unknown efficacy in patients with stable chronic obstructive pulmonary disease (COPD) and resting

95 Worldwide, chronic obstructive pulmonary disease (COPD) and stroke

96 Asthma and chronic obstructive pulmonary disease (COPD) are highly

97 ms driving persistent airway inflammation in chronic obstructive pulmonary disease (COPD) are incompl

98 eta2-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) are limited

99 Patients with chronic obstructive pulmonary disease (COPD) are suscept

100 spnea in interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) are unknown

101 ) is an established complication of advanced chronic obstructive pulmonary disease (COPD) associated

102 is a paucity of studies comparing asthma and chronic obstructive pulmonary disease (COPD) based on th

103 d pneumonia (CAP) incidence in patients with chronic obstructive pulmonary disease (COPD) by unknown

104 y regional lung ventilation in patients with chronic obstructive pulmonary disease (COPD) by using fr

105 Evidence for the management of chronic obstructive pulmonary disease (COPD) comes from

106 Chronic obstructive pulmonary disease (COPD) comprises c

107 e specific signaling networks in healthy and chronic obstructive pulmonary disease (COPD) contexts.

108 the frequency of ILC1 cells in patients with chronic obstructive pulmonary disease (COPD) correlated

109 CNVs) in susceptible regions have effects on chronic obstructive pulmonary disease (COPD) development

110 al hospital with signs and symptoms of acute chronic obstructive pulmonary disease (COPD) exacerbatio

111 Hi) is the leading bacterial pathogen during chronic obstructive pulmonary disease (COPD) exacerbatio

112 r high blood eosinophils are associated with chronic obstructive pulmonary disease (COPD) exacerbatio

113 LE: During noninvasive ventilation (NIV) for chronic obstructive pulmonary disease (COPD) exacerbatio

114 n, the pharmaceutical industry, and academic chronic obstructive pulmonary disease (COPD) experts wit

115 RATIONALE: Patients with chronic obstructive pulmonary disease (COPD) frequently

116 Since Chronic Obstructive Pulmonary disease (COPD) has emerged

117 re some patients with features of asthma and chronic obstructive pulmonary disease (COPD) has highlig

118 dherence to inhaled therapy by patients with chronic obstructive pulmonary disease (COPD) has not bee

119 role in other respiratory conditions such as chronic obstructive pulmonary disease (COPD) has not bee

120 ations of eosinophils in blood and sputum in chronic obstructive pulmonary disease (COPD) have been a

121 People with advanced chronic obstructive pulmonary disease (COPD) have distre

122 y between smoking behavior and lung function/chronic obstructive pulmonary disease (COPD) have not be

123 ned in these particles to infect healthy and chronic obstructive pulmonary disease (COPD) human cilia

124 costs and number of deaths among people with chronic obstructive pulmonary disease (COPD) in England

125 been identified as a susceptibility gene for chronic obstructive pulmonary disease (COPD) in genome-w

126 rticles (EMPs) are emerging as biomarkers of chronic obstructive pulmonary disease (COPD) in individu

127 an association between childhood asthma and chronic obstructive pulmonary disease (COPD) in later li

128 The association of asthma and chronic obstructive pulmonary disease (COPD) in the same

129 The burden of chronic obstructive pulmonary disease (COPD) in the USA

130 RATIONALE: Acute exacerbations of chronic obstructive pulmonary disease (COPD) increase th

131 RATIONALE: Chronic obstructive pulmonary disease (COPD) is a chroni

132 Chronic obstructive pulmonary disease (COPD) is a comple

133 Chronic obstructive pulmonary disease (COPD) is a comple

134 Chronic obstructive pulmonary disease (COPD) is a comple

135 Chronic obstructive pulmonary disease (COPD) is a condit

136 Chronic obstructive pulmonary disease (COPD) is a devast

137 Chronic obstructive pulmonary disease (COPD) is a global

138 Chronic obstructive pulmonary disease (COPD) is a leadin

139 Chronic obstructive pulmonary disease (COPD) is a leadin

140 Chronic obstructive pulmonary disease (COPD) is a risk f

141 Chronic obstructive pulmonary disease (COPD) is associat

142 Chronic obstructive pulmonary disease (COPD) is characte

143 Chronic obstructive pulmonary disease (COPD) is characte

144 Chronic obstructive pulmonary disease (COPD) is characte

145 Chronic obstructive pulmonary disease (COPD) is characte

146 Chronic obstructive pulmonary disease (COPD) is characte

147 RATIONALE: Chronic obstructive pulmonary disease (COPD) is characte

148 f factors contributing to the development of chronic obstructive pulmonary disease (COPD) is crucial

149 RATIONALE: The burden of chronic obstructive pulmonary disease (COPD) is increasi

150 RATIONALE: The prevalence of chronic obstructive pulmonary disease (COPD) is increasi

151 nd systemic inflammation among patients with chronic obstructive pulmonary disease (COPD) is largely

152 Chronic obstructive pulmonary disease (COPD) is linked t

153 RATIONALE: Chronic obstructive pulmonary disease (COPD) is often un

154 Chronic obstructive pulmonary disease (COPD) is regarded

155 and its clinical relevance in patients with chronic obstructive pulmonary disease (COPD) is scarce.

156 With increasingly aging populations, chronic obstructive pulmonary disease (COPD) is the four

157 nimal model of cigarette smoke (CS) -induced chronic obstructive pulmonary disease (COPD) is the prim

158 Chronic obstructive pulmonary disease (COPD) is the thir

159 The role of fibrocytes in chronic obstructive pulmonary disease (COPD) is unknown.

160 Dyspnoea in chronic obstructive pulmonary disease (COPD) may be link

161 Epidemiologic evidence suggested chronic obstructive pulmonary disease (COPD) might incre

162 Chronic obstructive pulmonary disease (COPD) occurs in a

163 Chronic obstructive pulmonary disease (COPD) often coexi

164 tum extracts in order to study the effect of Chronic Obstructive Pulmonary Disease (COPD) on the lung

165 8,475 subjects (99%) were assigned as having chronic obstructive pulmonary disease (COPD) or no COPD.

166 Some of the Chronic Obstructive Pulmonary Disease (COPD) patients en

167 ly trivial infection; however, in asthma and chronic obstructive pulmonary disease (COPD) patients, t

168 stratify exacerbation risk in patients with chronic obstructive pulmonary disease (COPD) rely on a h

169 Many individuals with chronic obstructive pulmonary disease (COPD) remain undi

170 Emerging models for predicting risk of chronic obstructive pulmonary disease (COPD) require ext

171 Currently, the diagnosis of chronic obstructive pulmonary disease (COPD) requires a

172 Outcomes after exacerbations of chronic obstructive pulmonary disease (COPD) requiring a

173 Little is known about the natural history of chronic obstructive pulmonary disease (COPD) that has de

174 the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a

175 lung transplantation (n = 11) and those with chronic obstructive pulmonary disease (COPD) who were un

176 Patients with chronic obstructive pulmonary disease (COPD) with an eos

177 unaffected in patients with asthma and that chronic obstructive pulmonary disease (COPD), a conditio

178 guide pharmacological treatment decisions in chronic obstructive pulmonary disease (COPD), a personal

179 ven percent (52 of 78) of patients exhibited chronic obstructive pulmonary disease (COPD), although o

180 ng of respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD), and critic

181 ut 14% of US adults aged 40 to 79 years have chronic obstructive pulmonary disease (COPD), and it is

182 Respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and lung i

183 nonaccidental cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), and lung-c

184 iratory infections (ARI), asthma, pneumonia, chronic obstructive pulmonary disease (COPD), and upper

185 Most airway diseases, including chronic obstructive pulmonary disease (COPD), are associ

186 ral role in identifying subphenotypes within chronic obstructive pulmonary disease (COPD), asthma, an

187 osteroids are important in the management of chronic obstructive pulmonary disease (COPD), but can sl

188 been observed in the airway in patients with chronic obstructive pulmonary disease (COPD), but their

189 y virus (HIV) are features of HIV-associated chronic obstructive pulmonary disease (COPD), but these

190 RATIONALE: Chronic obstructive pulmonary disease (COPD), in particu

191 In chronic obstructive pulmonary disease (COPD), lymphoid f

192 uses combined and for heart disease, cancer, chronic obstructive pulmonary disease (COPD), stroke, un

193 RATIONALE: In chronic obstructive pulmonary disease (COPD), the benefi

194 n to diabetes, hyperlipidemia, hypertension, chronic obstructive pulmonary disease (COPD), ulcer hist

195 In applying CONDOR to eQTLs in chronic obstructive pulmonary disease (COPD), we found t

196 ially in older individuals and in those with chronic obstructive pulmonary disease (COPD), whereas sh

197 the case of a 63-year-old man suffering from chronic obstructive pulmonary disease (COPD), who presen

198 r amplified by the tumor-enhancing effect of chronic obstructive pulmonary disease (COPD)-type airway

199 or replication of gene expression studies in chronic obstructive pulmonary disease (COPD).

200 ercentage predicted of FEV1 in patients with chronic obstructive pulmonary disease (COPD).

201 chodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease (COPD).

202 ACOS) is associated with worse outcomes than chronic obstructive pulmonary disease (COPD).

203 consumption has been studied in relation to chronic obstructive pulmonary disease (COPD).

204 h progressive respiratory diseases including chronic obstructive pulmonary disease (COPD).

205 ents of lung structure in conditions such as chronic obstructive pulmonary disease (COPD).

206 nd exercise intolerance are common in severe chronic obstructive pulmonary disease (COPD).

207 protein (HHIP) are robustly associated with chronic obstructive pulmonary disease (COPD).

208 Exacerbations are a hallmark of chronic obstructive pulmonary disease (COPD).

209 smoking-associated emphysema, a component of chronic obstructive pulmonary disease (COPD).

210 se reduces exercise hyperpnoea in health and chronic obstructive pulmonary disease (COPD).

211 ers, asymptomatic smokers, and patients with chronic obstructive pulmonary disease (COPD).

212 m considered concurrently as determinants of chronic obstructive pulmonary disease (COPD).

213 lated miRNAs in lung tissue of patients with chronic obstructive pulmonary disease (COPD).

214 C]) is associated with cigarette smoking and chronic obstructive pulmonary disease (COPD).

215 major barrier to the effective treatment of chronic obstructive pulmonary disease (COPD).

216 in the emphysematous lungs of patients with chronic obstructive pulmonary disease (COPD).

217 with chronic hypoxemia in disorders such as chronic obstructive pulmonary disease (COPD).

218 e role of physical activity in the course of chronic obstructive pulmonary disease (COPD).

219 n cause of airway infections associated with chronic obstructive pulmonary disease (COPD).

220 lung, and are essential to the diagnosis of chronic obstructive pulmonary disease (COPD).

221 of morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD).

222 enescence is involved in the pathogenesis of chronic obstructive pulmonary disease (COPD).

223 t is a therapeutic agent in the treatment of chronic obstructive pulmonary disease (COPD).

224 nstay of pharmacological treatment of stable chronic obstructive pulmonary disease (COPD).

225 f inflammation and airway wall remodeling in chronic obstructive pulmonary disease (COPD).

226 eadmissions for select conditions, including chronic obstructive pulmonary disease (COPD).

227 corticosteroid efficacy in the management of chronic obstructive pulmonary disease (COPD).

228 influenzae (NTHi) persists in the airways in chronic obstructive pulmonary disease (COPD).

229 hysical activity is a key therapeutic aim in chronic obstructive pulmonary disease (COPD).

230 chodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease (COPD).

231 been shown to exert therapeutic efficacy in chronic obstructive pulmonary disease (COPD).

232 rbations in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

233 sults on a whole-lung basis in patients with chronic obstructive pulmonary disease (COPD).

234 function impairment that was consistent with chronic obstructive pulmonary disease (COPD); these part

235 tients with comorbid allergy (P = 0.045) and chronic obstructive pulmonary disease (COPD; P = 0.015).

236 .7-2.3 for lung cancer (LC; P=4.0 x 10(-4)), chronic obstructive pulmonary disease (COPD; P=9.3 x 10(

237 act inflammatory diseases such as asthma and chronic obstructive pulmonary diseases (COPD) affect mor

238 ata in the COPDGene (Genetic Epidemiology of Chronic Obstructive Pulmonary Disease [COPD]; non-Hispan

239 ation package to the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene) study t

240 haled air are necessary parameters to detect chronic obstructive pulmonary diseases (COPDs) such as a

241 in baseline age, body mass index, diabetes, chronic obstructive pulmonary disease, coronary artery d

242 common among smokers and is associated with chronic obstructive pulmonary disease development and pr

243 y of coronary artery disease, heart failure, chronic obstructive pulmonary disease, diabetes mellitus

244 r risk factors for the various phenotypes of chronic obstructive pulmonary disease during different s

245 race, ethnicity, education, body mass index, chronic obstructive pulmonary disease, emphysema, person

246 mon chronic lung diseases such as asthma and chronic obstructive pulmonary disease, estimating physio

247 in a substantial proportion of patients with chronic obstructive pulmonary disease, even after smokin

248 not achieve better outcomes of patients with chronic obstructive pulmonary disease exacerbation treat

249 ad and outcomes among patients with an acute chronic obstructive pulmonary disease exacerbation.

250 RATIONALE: Chronic obstructive pulmonary disease exacerbations are

251 ovirus is linked to asthma exacerbations and chronic obstructive pulmonary disease exacerbations in a

252 Pharmacologic treatment of chronic obstructive pulmonary disease has consistent ben

253 RATIONALE: Genetic association studies in chronic obstructive pulmonary disease have primarily tes

254 and poor exercise ventilatory efficiency in chronic obstructive pulmonary disease-heart failure over

255 isease (HR, 1.66; 95% CI, 1.41-1.95), severe chronic obstructive pulmonary disease (HR, 1.39; 95% CI,

256 nce rates for asthma in children and adults, chronic obstructive pulmonary disease, hypertension, dia

257 lion (1.6 million to 6.8 million) DALYs from chronic obstructive pulmonary disease in 2015.

258 as coronary disease, left heart failure, and chronic obstructive pulmonary disease in not-operated pa

259 nurse-led self-management for patients with chronic obstructive pulmonary disease in primary care.

260 bstructive lung diseases, such as asthma and chronic obstructive pulmonary disease, include not only

261 seases affecting the lung, including asthma, chronic obstructive pulmonary disease, infections, and c

262 We defined the transcriptional repertoire of chronic obstructive pulmonary disease, IPF, or normal hi

263 Chronic obstructive pulmonary disease is characterized,

264 BACKGROUND AND Chronic obstructive pulmonary disease is increasing in p

265 established at birth and predisposes them to chronic obstructive pulmonary disease later in life.

266 emic heart disease, cerebrovascular disease, chronic obstructive pulmonary disease, lung cancer, and

267 l cohorts: a small asthma cohort and a large chronic obstructive pulmonary disease metaanalysis cohor

268 cular risk factor profile but with increased chronic obstructive pulmonary disease, migraine, and aff

269 other inflammatory disease models including chronic obstructive pulmonary disease, multiple sclerosi

270 in community settings to limit the impact of chronic obstructive pulmonary disease on everyday life o

271 idney disease (OR, 0.46; 95% CI, 0.36-0.59), chronic obstructive pulmonary disease (OR, 0.62; 95% CI,

272 (OR, 1.25; 95% CI, 1.12-1.39; P < .001), and chronic obstructive pulmonary disease (OR, 1.26; 95% CI,

273 2004 and 2014 for interstitial lung disease, chronic obstructive pulmonary disease, or pulmonary arte

274 R 1.99; arthritis; OR 1.71; asthma: OR 1.56; chronic obstructive pulmonary disease: OR 1.65; cancer:

275 This has been called the asthma-chronic obstructive pulmonary disease overlap syndrome (

276 mortality (p = 0.88), 30-day readmission for chronic obstructive pulmonary disease (p = 0.83), or hos

277 ical characteristics (older age, female sex, chronic obstructive pulmonary disease; P<0.05 for all),

278 5.7], except for initial diagnosis with more chronic obstructive pulmonary disease patients and less

279 y RV dysfunction and remodeling in nonsevere chronic obstructive pulmonary disease patients with a PA

280 sity, moderately impaired ejection fraction, chronic obstructive pulmonary disease, peripheral vascul

281 Chronic obstructive pulmonary disease prevalence was hig

282 all individuals except those with asthma or chronic obstructive pulmonary disease produced similar r

283 with epithelial cells from individuals with chronic obstructive pulmonary disease recapitulated feat

284 and concomitant IL-1beta responses occur in chronic obstructive pulmonary disease, respiratory infec

285 Patients with cystic fibrosis, chronic obstructive pulmonary disease, severe asthma, pr

286 progressively increased from mild to severe chronic obstructive pulmonary disease severity.

287 n patients [5%]), pneumonia (nine [5%]), and chronic obstructive pulmonary disease (six [3%]).

288 e and daily mortality due to respiratory and chronic obstructive pulmonary disease specifically were

289 enriched for rare variation contributing to chronic obstructive pulmonary disease susceptibility.

290 PINE2 is a candidate susceptibility gene for chronic obstructive pulmonary disease, the physiologic r

291 ross-sectional study of 13,893 patients with chronic obstructive pulmonary disease treated with nonin

292 ascular diseases, chronic kidney disease and chronic obstructive pulmonary disease were important ris

293 Forty-five hyperinflated patients with chronic obstructive pulmonary disease were randomized (1

294 reatest importance in mild-to-moderate stage chronic obstructive pulmonary disease where the rate of

295 e gut (inflammatory bowel disease) and lung (chronic obstructive pulmonary disease), where they contr

296 iately selected critically ill patients with chronic obstructive pulmonary disease while also highlig

297 in America that included 7,892 patients with chronic obstructive pulmonary disease who enrolled betwe

298 We enrolled stable outpatients with chronic obstructive pulmonary disease who had a forced e

299 Patients with chronic obstructive pulmonary disease, who had at least

300 g Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple